Our deals: Miracor Medical closes deal with Yonghua for series E round

Supporting the € 24M financing round and contribution of Chinese capital

Miracor Medical, a Belgian medical device company focused on severe cardiac disease treatments, announced the successful closing of a € 24M series E round of financing.

The round was led by a new corporate strategic investor joined by co-investor Yonghua. Current investors Earlybird, Noshaq, Quest for Growth, SFPI-FPIM, SRIW and another corporate strategic investor also supported this financing.
Miracor Medical has developed the PiCSO Impulse System, the first and only coronary sinus intervention designed to reduce infarct size, improve cardiac function by clearing microcirculation and potentially reduce the onset of heart failure following acute myocardial infarction.

The PiCSO Impulse System had received ‘Breakthrough Designation’ from the FDA in 2019 and recently the CE-Mark in June 2020. 

The funds will be used to advance the clinical study programs of the PiCSO Impulse System in Europe and the US. Additionally, commercialization will start in Europe.

How Agio Capital & Business Solutions helped

Agio introduced Miracor Medical to potential Chinese investors and supported the capital contribution from Chinese investor Yonghua. The addition of the Chinese investors to the syndicate broadens the investor base and provides access to the Greater China market.

For more information read the full press release.

More on subject(s)   Follow us at LinkedIn

Stay up to date